Core Viewpoint - The company, Rebio Biotech-B (06938.HK), is planning a global offering of 27.4874 million H-shares, with a proposed price of HKD 57.97 per share, aiming to raise approximately HKD 1.4736 billion for various research and development initiatives [1][3]. Group 1: Offering Details - The company intends to issue 27.4874 million H-shares, with 2.7488 million shares available in Hong Kong and 24.7386 million shares for international offering, subject to adjustments [1]. - The subscription period for the shares is set from December 31, 2025, to January 6, 2026, with trading expected to commence on January 9, 2026 [1]. - The shares will be sold at a price of HKD 57.97 each, with a trading unit of 200 shares [1]. Group 2: Investment Agreements - The company has entered into cornerstone investment agreements, with investors agreeing to purchase shares totaling approximately USD 100 million (around HKD 778 million) at the offering price [2]. - The cornerstone investors include various entities such as Arc Avenue Asset Management, Bright Stone Holdings, and several funds and investment firms [2]. Group 3: Use of Proceeds - The estimated net proceeds of approximately HKD 1.4736 billion will be allocated as follows: - About 37.4% for the development of the core product RBD4059 - Approximately 19.6% for RBD5044 - Around 15.9% for RBD1016 - About 10.1% for funding preclinical trial stage assets - Approximately 8.9% for advancing preclinical assets not yet in trials - About 8.1% for working capital and general corporate purposes [3].
瑞博生物-B(06938.HK)拟全球发售2748.74万股H股 引入华夏基金等多家基石
Ge Long Hui·2025-12-30 23:49